Metabolomic Profiling Reveals New Neuroactive Targets for Managing Psychological Symptoms in Alcohol Use Disorder

Kernekoncepter

Chronic alcohol abuse and short-term abstinence alter the blood metabolome, with changes in lipids, microbial metabolites, and caffeine derivatives correlating with psychological symptoms like anxiety, depression, and alcohol craving in patients with alcohol use disorder.

Resumé

This study investigated the impact of chronic alcohol abuse and short-term alcohol abstinence on the blood metabolome of patients with alcohol use disorder (AUD). Using non-targeted LC-MS metabolomics analysis, the researchers found several key insights:

Chronic alcohol abuse led to alterations in the plasma levels of various lipids (long-chain fatty acids, phospholipids), short-chain fatty acids, bile acids, and microbial metabolites compared to healthy controls. Many of these changes were correlated with the amount of alcohol consumed.

After a 3-week alcohol withdrawal period, the blood metabolomic profile shifted towards the levels observed in healthy controls. This included changes in lipids, bilirubin, and caffeine metabolites like theobromine, paraxanthine, and theophylline.

Specific metabolites were significantly correlated with psychological symptoms like anxiety, depression, and alcohol craving in AUD patients. These included lipids (lysophosphatidylcholines, lysophosphatidylethanolamines), bile acids, and microbial co-metabolites (hippuric acid, pyrocatechol sulfate).

Many of the metabolites correlated with psychological symptoms, such as 3-hydroxyvaleric acid, caffeine derivatives, and microbial metabolites, were also detected in post-mortem brain samples from individuals with a history of heavy alcohol use, suggesting their potential neuroactive properties.

The findings indicate that metabolomic profiling can identify novel neuroactive targets derived from host-microbiome interactions that may be involved in the pathophysiology of AUD and related psychiatric symptoms. These metabolites could represent new therapeutic avenues for managing alcohol addiction and withdrawal.

Statistik

Compared to healthy controls, AUD patients had significantly higher levels of:

Long-chain fatty acids (16:1, 18:1, 22:4)
Phospholipids with these fatty acids
Glycinated bile acids (glycohyodeoxycholic acid, glycochenodeoxycholic acid)
Steroid hormones and acylcarnitines
4-pyridoxic acid (vitamin B6 metabolite)
Cotinine (nicotine metabolite)
3-hydroxyvaleric acid
AUD patients had significantly lower levels of:

Lysophosphatidylcholines with saturated odd-chain (15:0, 17:0) or polyunsaturated 18-carbon fatty acids
Ether-bond containing lipids
Furan fatty acids (3-CMPFP, CMPF)
Carotenoid compounds
Xanthine family metabolites (paraxanthine, theobromine, theophylline)
Amino acid-derived bacterial metabolites (pipecolic acid, 3-indole propionic acid, p-cresol sulfate, hippuric acid)

Citater

"Theobromine is known for its mood improving effect."
"Hippuric acid has been shown to be part of the causal pathway leading to depression."
"3-Hydroxyvaleric acid was significantly and positively correlated with anxiety and alcohol craving."

Vigtigste indsigter udtrukket fra

Blood metabolomic profiling reveals new targets in the management of psychological symptoms associated with alcohol use disorder

by Lecl... kl. www.biorxiv.org 02-29-2024

https://www.biorxiv.org/content/10.1101/2024.02.27.582239v1

Dybere Forespørgsler

How could the identified neuroactive metabolites be targeted therapeutically to manage psychological symptoms in alcohol use disorder?

The identified neuroactive metabolites, such as caffeine metabolites (theobromine, paraxanthine, and theophylline), 3-hydroxyvaleric acid, and microbial metabolites like hippuric acid and pyrocatechol sulfate, could be targeted therapeutically to manage psychological symptoms in alcohol use disorder (AUD) through several mechanisms:

Modulation of neurotransmitter systems: Caffeine metabolites act as adenosine receptor antagonists and phosphodiesterase inhibitors, influencing dopamine release and brain activity. By targeting these metabolites, it may be possible to modulate neurotransmitter systems involved in mood regulation and addiction.

Neuroprotection and neurotoxicity: Bile acids, including those identified in the study, have been shown to have both neuroprotective and neurotoxic effects. By targeting these metabolites, it may be possible to enhance neuroprotection and reduce neurotoxicity, thereby improving brain function and behavior in individuals with AUD.

Energy metabolism in the brain: Metabolites like 3-hydroxyvaleric acid serve as alternative energy sources in the brain. By targeting these metabolites, it may be possible to optimize energy metabolism in the brain, potentially improving cognitive function and mood regulation.

Inflammation and oxidative stress: Some of the identified metabolites have been associated with inflammation and oxidative stress. Targeting these metabolites could help reduce neuroinflammation and oxidative damage, which are common features of psychiatric disorders like AUD.

Overall, targeting these neuroactive metabolites could offer a novel therapeutic approach to managing psychological symptoms in AUD by modulating neurotransmitter systems, enhancing neuroprotection, optimizing energy metabolism, and reducing inflammation and oxidative stress in the brain.

How could the gut microbiome-derived metabolites like hippuric acid and pyrocatechol sulfate influence brain function and behavior?

Gut microbiome-derived metabolites like hippuric acid and pyrocatechol sulfate can influence brain function and behavior through several mechanisms:

Neurotransmitter modulation: These metabolites can interact with neurotransmitter systems in the brain, affecting mood, cognition, and behavior. For example, pyrocatechol sulfate has been implicated in synapse formation and fear extinction learning, while hippuric acid has been associated with neurodevelopment abnormalities and anxiety behavior.

Neuroinflammation: Gut-derived metabolites can modulate the immune response in the brain, leading to neuroinflammation. This neuroinflammation can impact neuronal function and contribute to the development of psychiatric symptoms.

Neuroprotection: Some gut-derived metabolites have neuroprotective properties, helping to maintain neuronal health and function. By influencing neuroprotection, these metabolites can support brain function and behavior.

Gut-brain axis communication: The metabolites produced by the gut microbiome can communicate with the brain through the gut-brain axis, influencing neural signaling, neurotransmitter release, and neuroendocrine responses. This bidirectional communication pathway plays a crucial role in regulating brain function and behavior.

Overall, gut microbiome-derived metabolites like hippuric acid and pyrocatechol sulfate can impact brain function and behavior by modulating neurotransmitter systems, influencing neuroinflammation, providing neuroprotection, and participating in the communication between the gut and the brain.

Could dietary or probiotic interventions that modulate the production of these metabolites be a viable strategy for preventing or treating alcohol-related psychiatric disorders?

Dietary or probiotic interventions that modulate the production of neuroactive metabolites from the gut microbiome could indeed be a viable strategy for preventing or treating alcohol-related psychiatric disorders like alcohol use disorder (AUD). Here's how these interventions could be beneficial:

Promoting a healthy gut microbiome: Dietary interventions rich in prebiotic fibers and probiotics can promote the growth of beneficial gut bacteria that produce neuroactive metabolites with positive effects on brain function and behavior. By modulating the gut microbiome composition, these interventions can influence the production of metabolites like hippuric acid and pyrocatechol sulfate.

Reducing inflammation and oxidative stress: Certain dietary components and probiotics have anti-inflammatory and antioxidant properties, which can help reduce neuroinflammation and oxidative stress in the brain. By targeting the production of metabolites associated with inflammation and oxidative stress, these interventions can support brain health and mental well-being.

Modulating neurotransmitter systems: Some dietary components and probiotics can influence neurotransmitter systems in the brain, impacting mood, cognition, and behavior. By promoting the production of neuroactive metabolites that modulate neurotransmitter function, these interventions can help regulate psychological symptoms in AUD.

Enhancing neuroprotection: Dietary interventions rich in antioxidants and anti-inflammatory compounds can enhance neuroprotection, safeguarding neurons from damage and supporting overall brain health. By modulating the production of neuroactive metabolites involved in neuroprotection, these interventions can contribute to the prevention and treatment of alcohol-related psychiatric disorders.

In conclusion, dietary or probiotic interventions that target the production of neuroactive metabolites from the gut microbiome offer a promising approach for preventing and treating alcohol-related psychiatric disorders by promoting a healthy gut microbiome, reducing inflammation and oxidative stress, modulating neurotransmitter systems, and enhancing neuroprotection in the brain.